

Prescribing Information

Betacap™ Scalp Application

Betamethasone valerate 0.1% w/w.

Uses: A potent topical corticosteroid for the treatment of steroid-responsive dermatoses of the scalp, such as psoriasis and seborrhoeic dermatitis.

Directions: For adults, the elderly and children over one year apply sparingly to the scalp night and morning until improvement is noticeable. Improvement may then be sustained with once daily application or less frequently. For seborrhoeic dermatitis in children do not use for longer than 5 to 7 days.

Contra-indications, warnings, side effects etc: Please refer to SPC for full details before prescribing. Do not use if sensitive to any of the ingredients. Not to be used where there is bacterial, fungal or viral infection of the scalp. Do not use in children under one year. Keep away from the eyes. Avoid continuous long-term treatment, particularly in children, as systemic side effects can occur even without occlusion. Long term use of topical steroids may result in rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which is more likely to occur when used on delicate skin sites such as the face and flexures. If used in psoriasis, careful patient supervision is required.

Prolonged use of large amounts or treatment of extensive areas can lead to features of steroid excess and suppression of the HPA axis, particularly in children and if occlusive dressings are used. Visual disturbance may be reported with systemic and topical corticosteroid use. Refer to an ophthalmologist if blurred vision or visual disturbances occur. Betacap is highly flammable, do not use near a naked flame and allow the treated scalp to dry naturally.

Package quantity, NHS price and MA number:

100ml plastic bottle with integral nozzle, £3.94, PL 00173/0149.

Legal category: POM.

MA holder: Dermal Laboratories, Tatmore Place, Gosmore, Hitchin, Herts, SG4 7QR, UK.

Date of preparation: March 2024.

'Betacap' is a trademark



Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Dermal.

To find out more information, visit <https://www.dermal.co.uk/healthcare-professionals/products/betacap-scalp-application/>